Article

2018-04-17 Economy

Goldman Sachs Analysts Question Whether Curing Patients Is Good for Business

h/t Instapundit
[Gizmodo] Recent advancements in science and medicine have put cures within reach for diseases that have long plagued humankind.

In a recent report, though, Goldman Sachs analysts posed an uncomfortable question that quickly sparked criticism.

"Is curing patients a sustainable business model?" analysts asked in an April 10 report entitled "The Genome Revolution," which CNBC first reported.

One-and-done cures enabled by gene editing, analyst Salveen Richter wrote in the note to clients this week, are near-miraculous innovations that stand to benefit patients immensely.

But they also present a challenge to business.

"While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow," she wrote.

Posted by g(r)omgoru 2018-04-17 10:43|| || Front Page|| [11135 views ] Top

#1 Rhetorical question of course.

Posted by Besoeker 2018-04-17 10:51|| 2018-04-17 10:51|| Front Page Top

#2 There will always be a need for genome fixing and cancer cures as there will always be issues.

So a one and done doesn't mean you develop and never use again. There will be another baby along the way that has issues.

Posted by DarthVader 2018-04-17 10:54|| 2018-04-17 10:54|| Front Page Top

#3 Except it shows you what's wrong with "Economics", Darth

Posted by g(r)omgoru 2018-04-17 11:15|| 2018-04-17 11:15|| Front Page Top

10:40 Procopius2k
10:39 Procopius2k
10:37 Besoeker
10:35 Besoeker
10:35 Elmerert Hupens2660
10:31 Frank G
10:29 Grom the Affective
10:27 Glenmore
10:26 Jack Fleling2104
10:23 Glenmore
10:13 Glenmore
10:11 Difar Dave
10:01 Old Patriot
10:00 NN2N1
09:58 EMS Artifact
09:55 EMS Artifact
09:48 Besoeker
09:43 magpie
09:35 Frank G
09:32 Mercutio
09:24 SteveS
09:09 Elmomoter Mussolini9149
09:03 Skidmark
08:53 Gleng Whaick2262